Literature DB >> 30154232

Functions of neutral ceramidase in the Golgi apparatus.

Wataru Sakamoto1,2,3, Nicolas Coant1,2, Daniel Canals1,2, Lina M Obeid1,2,4, Yusuf A Hannun5,2,6,7,8.   

Abstract

Ceramidases hydrolyze ceramides into sphingosine and fatty acids, with sphingosine being further metabolized into sphingosine-1-phosphate (S1P); thus, ceramidases control the levels of these bioactive sphingolipids in cells and tissues. Neutral ceramidase (nCDase) is highly expressed in colorectal tissues, and a recent report showed that nCDase activity is involved in Wnt/β-catenin signaling. In addition, the inhibition of nCDase decreases the development and progression of colorectal tumor growth. Here, to determine the action of nCDase in colorectal cancer cells, we focused on the subcellular localization and metabolic functions of this enzyme in HCT116 cells. nCDase was found to be located in both the plasma membrane and in the Golgi apparatus, but it had minimal effects on basal levels of ceramide, sphingosine, or S1P. Cells overexpressing nCDase were protected from the cell death and Golgi fragmentation induced by C6-ceramide, and they showed reduced levels of C6-ceramide and higher levels of S1P and sphingosine. Furthermore, compartment-specific metabolic functions of the enzyme were probed using C6-ceramide and Golgi-targeted bacterial SMase (bSMase) and bacterial ceramidase (bCDase). The results showed that Golgi-specific bCDase also demonstrated resistance against the cell death stimulated by C6-ceramide, and it catalyzed the metabolism of ceramides and produced sphingosine in the Golgi. Targeting bSMase to the Golgi resulted in increased levels of ceramide that were attenuated by the expression of nCDase, also supporting its ability to metabolize Golgi-generated ceramide. These results are critical in understanding the functions of nCDase actions in colorectal cancer cells as well as the compartmentalized pathways of sphingolipid metabolism.

Entities:  

Keywords:  Golgi; apoptosis; colon cancer; neutral ceramidase; sphingolipids

Mesh:

Substances:

Year:  2018        PMID: 30154232      PMCID: PMC6210901          DOI: 10.1194/jlr.M088187

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  43 in total

1.  Cloning and characterization of a novel human alkaline ceramidase. A mammalian enzyme that hydrolyzes phytoceramide.

Authors:  C Mao; R Xu; Z M Szulc; A Bielawska; S H Galadari; L M Obeid
Journal:  J Biol Chem       Date:  2001-05-16       Impact factor: 5.157

2.  C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth.

Authors:  Margaret Flowers; Gemma Fabriás; Antonio Delgado; Josefina Casas; Jose Luis Abad; Myles C Cabot
Journal:  Breast Cancer Res Treat       Date:  2011-09-21       Impact factor: 4.872

Review 3.  Preclinical development of a C6-ceramide NanoLiposome, a novel sphingolipid therapeutic.

Authors:  Mark Kester; Jocelyn Bassler; Todd E Fox; Carly J Carter; Jeff A Davidson; Mylisa R Parette
Journal:  Biol Chem       Date:  2015-06       Impact factor: 3.915

4.  Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase.

Authors:  K Hofmann; S Tomiuk; G Wolff; W Stoffel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 5.  An overview of sphingolipid metabolism: from synthesis to breakdown.

Authors:  Christopher R Gault; Lina M Obeid; Yusuf A Hannun
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

6.  Interleukin-1beta induces chronic activation and de novo synthesis of neutral ceramidase in renal mesangial cells.

Authors:  R Franzen; A Pautz; L Bräutigam; G Geisslinger; J Pfeilschifter; A Huwiler
Journal:  J Biol Chem       Date:  2001-07-16       Impact factor: 5.157

Review 7.  Discovery of the molecular machinery CERT for endoplasmic reticulum-to-Golgi trafficking of ceramide.

Authors:  Kentaro Hanada
Journal:  Mol Cell Biochem       Date:  2006-06       Impact factor: 3.396

8.  Structural Basis for Ceramide Recognition and Hydrolysis by Human Neutral Ceramidase.

Authors:  Michael V Airola; William J Allen; Michael J Pulkoski-Gross; Lina M Obeid; Robert C Rizzo; Yusuf A Hannun
Journal:  Structure       Date:  2015-07-16       Impact factor: 5.006

9.  Identification of a novel amidase motif in neutral ceramidase.

Authors:  Sehamuddin Galadari; Bill X Wu; Cungui Mao; Patrick Roddy; Samer El Bawab; Yusuf A Hannun
Journal:  Biochem J       Date:  2006-02-01       Impact factor: 3.857

Review 10.  FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.

Authors:  Volker Brinkmann
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

View more
  5 in total

1.  Probing compartment-specific sphingolipids with targeted bacterial sphingomyelinases and ceramidases.

Authors:  Wataru Sakamoto; Daniel Canals; Silvia Salamone; Janet Allopenna; Christopher J Clarke; Justin Snider; Lina M Obeid; Yusuf A Hannun
Journal:  J Lipid Res       Date:  2019-06-26       Impact factor: 5.922

Review 2.  Neutral ceramidase: Advances in mechanisms, cell regulation, and roles in cancer.

Authors:  Nicolas Coant; Yusuf A Hannun
Journal:  Adv Biol Regul       Date:  2018-10-26

Review 3.  Elusive Roles of the Different Ceramidases in Human Health, Pathophysiology, and Tissue Regeneration.

Authors:  Carolina Duarte; Juliet Akkaoui; Chiaki Yamada; Anny Ho; Cungui Mao; Alexandru Movila
Journal:  Cells       Date:  2020-06-02       Impact factor: 6.600

Review 4.  Role of Ceramidases in Sphingolipid Metabolism and Human Diseases.

Authors:  Farzana Parveen; Daniel Bender; Shi-Hui Law; Vineet Kumar Mishra; Chih-Chieh Chen; Liang-Yin Ke
Journal:  Cells       Date:  2019-12-04       Impact factor: 6.600

5.  Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice.

Authors:  Sarah Alsamman; Stephanie A Christenson; Amy Yu; Nadia M E Ayad; Meghan S Mooring; Joe M Segal; Jimmy Kuang-Hsien Hu; Johanna R Schaub; Steve S Ho; Vikram Rao; Megan M Marlow; Scott M Turner; Mai Sedki; Lorena Pantano; Sarani Ghoshal; Diego Dos Santos Ferreira; Hsiao-Yen Ma; Caroline C Duwaerts; Regina Espanol-Suner; Lan Wei; Benjamin Newcomb; Izolda Mileva; Daniel Canals; Yusuf A Hannun; Raymond T Chung; Aras N Mattis; Bryan C Fuchs; Andrew M Tager; Dean Yimlamai; Valerie M Weaver; Alan C Mullen; Dean Sheppard; Jennifer Y Chen
Journal:  Sci Transl Med       Date:  2020-08-19       Impact factor: 19.319

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.